Cargando…

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

BACKGROUND: Radioimmunotherapy has become one of the most promising strategies for cancer treatment. Preclinical and clinical studies have demonstrated that antiangiogenic therapy can improve the efficacy of immunotherapy and sensitize radiotherapy through a variety of mechanisms. However, it is und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Meng, Zhai, Yirui, Men, Yu, Zhao, Maoyuan, Sun, Xin, Ma, Zeliang, Bao, Yongxing, Yang, Xu, Sun, Shuang, Liu, Yunsong, Zhang, Wanting, Hui, Zhouguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825674/ https://www.ncbi.nlm.nih.gov/pubmed/35154567 http://dx.doi.org/10.1155/2022/5479491

Ejemplares similares

Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
por: Liu, Yunsong, et al.
Publicado: (2023)

Higher Lung and Heart Doses Decrease Early and Long-Term Survival, Respectively, in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation
por: Ma, Zeliang, et al.
Publicado: (2023)

Postoperative radiotherapy improves survival of patients with ypN2 non‐small cell lung cancer after neoadjuvant chemotherapy followed by surgery – A propensity score matching study of the Surveillance, Epidemiology, and End Results database
por: Bao, Yongxing, et al.
Publicado: (2021)

Risk of cardiac‐related mortality in stage IIIA‐N2 non‐small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Sun, Xin, et al.
Publicado: (2021)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Yuan, Meng, et al.
Publicado: (2021)

Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study
por: Yang, Xu, et al.
Publicado: (2021)

Enhanced prediction of postoperative radiotherapy‐induced esophagitis in non‐small cell lung cancer: Dosiomic model development in a real‐world cohort and validation in the PORT‐C randomized controlled trial
por: Ma, Zeliang, et al.
Publicado: (2023)

The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients
por: Yuan, Meng, et al.
Publicado: (2021)

Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis
por: Ma, Zeliang, et al.
Publicado: (2021)

Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta‐analysis
por: Bao, Yongxing, et al.
Publicado: (2022)

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins
por: Yuan, Meng, et al.
Publicado: (2020)

Multivariate gene expression‐based survival predictor model in esophageal adenocarcinoma
por: Zhao, Maoyuan, et al.
Publicado: (2020)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
por: Liu, Shaochuan, et al.
Publicado: (2020)

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer
por: Zheng, Wubin, et al.
Publicado: (2022)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
por: Zhou, Shujie, et al.
Publicado: (2023)

Combined neat model for the prognosis of postoperative stage III‐N2 non‐small cell lung cancer
por: Zhai, Yirui, et al.
Publicado: (2020)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Luo, Mei, et al.
Publicado: (2021)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

The mapping of mRNA alterations elucidates the etiology of radiation-induced pulmonary fibrosis
por: Yuan, Meng, et al.
Publicado: (2022)

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
por: Su, Yudong, et al.
Publicado: (2022)

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
por: Han, Dong, et al.
Publicado: (2022)

Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy
por: Garbow, Joel R., et al.
Publicado: (2021)

Reply: Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Bao, Yongxing, et al.
Publicado: (2022)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis
por: Sun, Shuang, et al.
Publicado: (2021)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness
por: Zhao, Maoyuan, et al.
Publicado: (2020)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
por: Sun, Yongkun, et al.
Publicado: (2016)

Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer
por: Gao, Qin, et al.
Publicado: (2020)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
por: Zhen, Hongchao, et al.
Publicado: (2023)

Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy
por: Fan, Peng, et al.
Publicado: (2022)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

MiR-323a-3p acts as a tumor suppressor by suppressing FMR1 and predicts better esophageal squamous cell carcinoma outcome
por: Men, Yu, et al.
Publicado: (2022)

Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer
por: Yu, Ping, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
por: Li, Xiao-Yuan, et al.
Publicado: (2022)

Serum Eicosanoids Metabolomics Profile in a Mouse Model of Renal Cell Carcinoma: Predicting the Antitumor Efficacy of Anlotinib
por: Du, Ping, et al.
Publicado: (2022)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qugn7mnsbqrbm8a5v6bvevrqtk